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Backgrounds: The role of interim PET/CT in peripheral T-cell lymphoma (PTCL) is less identified compared to other
subtype of lymphoma. This study prospectively investigated the prognostic accuracy of sequential interim PET/CT
using visual and quantitative assessment to determine whether it provided prognostic information for the
treatment of PTCL.
Methods: Sixty-three patients with newly diagnosed PTCL were enrolled, and 59 patients underwent interim
PET/CT after three or four courses of induction treatment. The response of interim PET/CT was assessed by three
parameters: the Deauville five-point scale (5-PS), ΔSUVmax, and ΔMTV2.5.
Results: Over a median follow up of 40.3 months, each assessment of interim PET/CT using the 5-PS, ΔSUVmax,
and ΔMTV2.5 had predictive value for progression-free survival. To increase the predictive accuracy of interim
PET/CT, we divided patients into three groups according to the sum of scores for three adverse responses based
on the visual, SUV-based and MTV-based assessment: favorable, intermediate, and poor responder. The clinical
outcome of patients in the favorable group was significantly superior to patients in the poor or intermediate group.
Conclusion: Visual, quantitative SUV-based, and MTV-based assessment in interim PET/CT are valuable for early treatment
response assessment in patients with PTCL, and the combined approach using the three parameters was more efficient
in discriminating between patients with different survival outcomes compared with single-parameter assessment.
Trial registration: NCT01470066.
Keywords: Peripheral T-cell lymphoma, Positron emission tomography, Interim PET/CT, Prognosis, Prognostic modelBackground
Peripheral T-cell lymphoma (PTCL) is a heterogeneous
group of aggressive lymphomas, in which the T-cell
phenotype itself is associated with unfavorable prognos-
tic factors compared with B-cell-phenotype lymphomas
[1]. Although PTCL is chemosensitive to conventional
regimens, the clinical outcomes have been uniformly
disappointing. To improve the therapeutic outcome,
frontline high-dose chemotherapy followed by autolo-
gous stem cell transplantation (HDT/ASCT) or early* Correspondence: drydh1685@hotmail.com
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unless otherwise stated.therapeutic intensification based on the interim response
has been presented as a rescue option from poor prog-
nosis. However, the effect on distinct PTCL subtypes,
the optimal time point of assessing the response during
the clinical course, and the prognostic factors for pre-
dicting better outcomes remain unclear [2-4].
Several recent studies have evaluated treatment of
patients with Hodgkin’s or Non-Hodgkin’s lymphoma
using dose-dense therapeutic intensification based on as-
sessment of interim positron emission tomography
(PET) with 18F-fluoro-2-deoxy-D-glucose (FDG) to pre-
dict outcome [5-8]. Persistent FDG uptake during pri-
mary chemotherapy is associated with a poor prognosis
and could be considered to escalate treatment strategieshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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fication using the interim metabolic response remains
controversial, and its clinical use is not permitted, except
in clinical trials. Moreover, the lack of agreed-upon stan-
dardized response criteria, difference in the percent risk
according to the international prognostic index (IPI) or
prognostic index of peripheral T-cell lymphoma (PIT),
and different treatment modalities used have contributed
to the variability of outcomes and poor reproducibility
[9-11]. In an attempt to standardize the reporting cri-
teria of interim PET/CT, the ‘International Workshop
on Interim PET in Lymphoma’ suggested visual response
criteria using the Deauville five-point scale (5-PS) and
investigated the standardized uptake value (SUV) in
comparison with this visual system [12,13]. Methods to
improve the predictive value of interim PET/CT include
quantitative approaches, such as measuring the rate of
reduction in maximum SUV (ΔSUVmax) or metabolic
tumor volume (ΔMTV), defined as the volume of tumor
tissue with increased FDG uptake. A quantitative ap-
proach might be more appropriate in the early response
of PET to reduce the false-positive rate or decrease the
inter-observer variability in interpretation [14-16].
Data concerning the role of PET/CT in patients with
PTCLs using interim assessment with FDG uptake are
limited. T/NK cell lymphomas are mostly FDG avid,
with higher uptake in more aggressive subtypes but
lower uptake in cutaneous disease [17-19]. However,
because FDG is not a tumor-specific substance, it may
accumulate in various benign conditions, possibly pro-
ducing false-positive results. The prognostic significance
of positive interim FDG-PET/CT based on visual assess-
ment may be reduced by tracer uptake by inflammatory
or infectious lesions, particularly lymphoma at special
sites or anatomical FDG uptakes in patients with nasal
NK/T or with extranodal PTCLs [20,21]. Thus, the com-
bination of visual and quantitative assessments could
decrease the pitfalls of interim PET/CT interpretation.
Therefore, interim PET/CT assessed by visual, SUV-based
or MTV-based parameters could enable the early identi-
fication of a poor prognosis and allow treatment intensi-
fication or early stem cell transplantation in PTCLs. In
the present study, we prospectively investigated the
prognostic accuracy of sequential interim PET/CT using
visual and quantitative assessment to determine whether
it provided prognostic information for the treatment
of PTCL.
Methods
Patients and study design
Sixty-three patients with newly diagnosed PTCL were
enrolled from September 2006 to November 2011 (Clini-
calTrials.gov Identifier: NCT01470066). The histological
diagnosis of PTCLs was made by hematopathologistsaccording to the World Health Organization (WHO)
classification, and all of the biopsy specimens were
reviewed through immunohistochemical examination and
molecular studies. PET/CT was performed at the time of
diagnosis, mid-treatment and the completion of primary
chemotherapy. Briefly, all of the patients had an initial CT
and PET/CT at diagnosis, a subsequent interim CT and
PET/CT after three or four cycles as well as at the comple-
tion of cyclophosphamide, doxorubicin, vincristine, pred-
nisone (CHOP)/CHOP-like, or non-anthracycline-based
chemotherapy. The interim response evaluation using
PET/CT was performed at 1 day prior to a scheduled
chemotherapy. The final response was assessed within
1 month of completing the primary chemotherapy, with
follow-up restaging every 3 months during the first year,
and every 6 months thereafter. All patients, except those
in stage I, were treated with six or eight cycles of an
anthracycline-based regimen (CHOP or CHOP-like),
dose-adjusted etoposide, vincristine, doxorubicin, cyclo-
phosphamide, and prednisone (EPOCH), VIDL (ifospha-
mide, etoposide, dexamethasone and L-asparaginase) or
IMEP (ifosphamide, methotrexate, etoposide, and prednis-
olone) as induction chemotherapy. Patients in stage I were
treated with four cycles of primary chemotherapy followed
by involved field radiation therapy (IFRT, 30 Gy). The
prognostic importance was classified according to the
International Prognostic Index (IPI) and Prognostic Index
for PTCL (PIT) (age, lactate dehydrogenase [LDH], per-
formance status, and bone marrow involvement). All
patients were eligible for inclusion after the protocol was
approved by the Institutional Review Board of Chonnam
National University Hwasun Hospital in accordance with
the Declaration of Helsinki. All patients provide written
informed consent before enrollment.
18F-FDG PET/CT and image analysis
All of the patients underwent 18F-FDG PET/CT using a
Discovery ST PET/CT system (GE Healthcare), consisting
of a bismuth germanate full scanner and a 16-detector-row
CT scanner. The patients fasted for at least 6 h prior to the
intravenous administration of 18F-FDG (7.4 MBq per body
weight) to ensure a serum glucose level below 7.2 mmol/L.
At 60 min after 18F-FDG administration, transmission data
were acquired using low-dose CT (120 kV, automated from
10 to 130 mA, a 512 × 512 matrix, a 50-cm field of view
(FOV), 3.75-mm slice thickness, and a rotation time of
0.8 s), extending from the base of the skull to the proximal
thighs. Immediately after CT acquisition, PET emission
scans were acquired in the same anatomic locations with a
15.7-cm axial FOV acquired in the two-dimensional mode
with a 128 × 128 matrix. The CT data were used for at-
tenuation correction. The images were reconstructed using
a conventional iterative algorithm (OSEM). A workstation
(AW Volume Share™) providing multi-planar reformatted
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The initial and final conventional CT and PET/CT were
assessed according to the revised International Workshop
Criteria (IWC) [22]. The PET/CT scans were read by two
nuclear medicine physicians who had no knowledge of
subject or clinical information.
Response of interim PET/CT based on the three parameters
of visual, SUV-based and MTV-based assessment
We first classified patients using the five-point scale
(5-PS) based on the Deauville criteria on interim PET/CT
analysis [12]: 1, no uptake; 2, uptake ≤mediastinum; 3,
uptake >mediastinum but ≤ liver; 4, uptake moderately
increased compared with the liver uptake at any site;
5, markedly increased uptake compared with the liver at
any site and new sites and/or new sites of disease. Interim
PET/CT images were graded as negative or positive by
comparison with initial PET/CT scans, and grades 1–3
were considered negative, and grades 4–5 were considered
positive [23]. This grading process was independent of the
size of the residual tumor.
Second, we classified the patients using the quantita-
tive analysis of 18F-FDG uptake changes based on the
percentage of SUVmax reduction between the initial and
interim PET/CT scans. On axial, coronal, or sagittal
coregistered PET/CT slices, simple circular regions of
interest (ROIs) were placed to cover the lesion or back-
ground. SUV measurements were corrected for body
weight according to the following standard formula:
Mean ROI activity (MBq/ml)/[Injected dose (MBq)/Body
weight (kg)] [24]. For each PET dataset, the maximum
SUV (SUVmax) was defined as the highest SUV among
all hypermetabolic tumor foci. The SUVmax reduction
rate (ΔSUVmax) was calculated as follows:
ΔSUVmax %ð Þ ¼ 100  ½SUVmax initialð Þ
– SUVmax interimð Þ=SUVmax initialð Þ
If all of the lesions had disappeared on interim PET,
ROIs were drawn in the same area on interim PET as on
baseline PET.
We finally classified patients using quantitative ana-
lysis of metabolic volume changes based on the percent-
age of MTV reduction (ΔMTV) between the initial and
interim PET/CT scans. To define the exact tumor mar-
gins around the target lesions, SUV2.5 was used follow-
ing previous reports [25,26], indicating that the tumor
volume area in PET/CT was delineated by a circle
encompassing regions with an SUV cutoff value of 2.5.
MTV2.5 was measured using the AW Volume Share™
workstation (GE Healthcare) on the fused PET/CT im-
ages [27]. AW Volume Share™ allows automatic registra-
tion and fusion between two volumetric acquisitions
that originate from different acquisition modalities. Theactive MTV2.5 was measured in a three-dimensional
manner by selecting the volume of interest (VOI) on the
axial image, and the VOI size was manually regulated on
the corresponding coronal and sagittal images to include
entire active tumors in the VOI. The SUVmax and sum
of the tumor volumes in all of the hypermetabolic tumor
foci were computed automatically by the program. The
MTV2.5 reduction rate (ΔMTV2.5) was calculated by
the same formula used for ΔSUVmax.
Statistical analysis
Progression-free survival (PFS) was used as an endpoint to
evaluate the prognostic significance of interim PET/CT.
PFS was calculated from the treatment start time to the first
recording of disease progression, death from any cause or
loss of follow-up period. Overall survival (OS) was defined
as the period from the start of treatment to the date of the
last follow up or death from any cause. Patients whose dis-
ease did not progress would be censored using the date at
which they were last known to show no progression. The
distribution of patients for OS and PFS was estimated using
the Kaplan–Meier method and were compared by the log-
rank test for the association between clinical prognostic fac-
tors and the probability of treatment failure.
To evaluate the optimal cutoff value of SUVmax or the
MTV2.5 reduction rate for predicting the PFS, receiver-
operating characteristic (ROC) analysis was performed. A
large area under the ROC curve (AUC) indicates greater
predictive power for survival. An AUC less than 0.5 indi-
cates no predictive ability, whereas an AUC greater than
0.5 represents predictive ability statistically. The multivari-
ate Cox’s proportional-hazards model was used to analyze
all influences found to be significant in the univariate
analysis. Probability values less than 0.05 were deemed
to indicate statistical significance, and the results were
expressed as means ± standard error of the mean (SEM).
Results
Patients’ characteristics and outcome
The clinical characteristics of the 63 enrolled patients are
summarized in Table 1. Their median age was 60 years
(range, 20–81 years) with 49.2% of patients aged more
than 60 years. Thirty-nine patients (61.9%) presented with
advanced-stage disease, and 18 (28.6%) had bone marrow
involvement. The histological subtypes were PTCL un-
specified (n = 17; 27%), angioimmunoblastic T-cell lymph-
oma (n = 10; 15.9%), NK/T cell (n = 27; 42.9%), and others.
Thirty-one patients (49.2%) were classified as high risk
based on IPI, and 29 (46%) were classified as high risk
(more than 2 factors) based on PIT. Most patients (84.1%)
were treated with the CHOP/CHOP-like regimen with a
median number of six cycles, and 10 (15.9%) were treated
with other induction chemotherapy including IMVP,
EPOCH, and VIDL. Fifteen patients, primarily with NK/T




Median age in years (range) 60 (20–81)
Histology
PTCL-U 17 27.0
Anaplastic large cell (ALK-negative) 6 (3) 9.5
Angioimmunoblastic 10 15.9
Extranodal NK/T cells 27 42.9
Enteropathy-associated 1 1.6
Systemic cutaneous or mycosis fungoides 1 1.6




B symptoms 26 41.3





0/1 factor 12/22 19.0/34.9
2 factors 14 22.2
3-4 factors 15 23.8
Primary chemotherapy
CHOP/ CHOP-like 53 84.1
Others (IMVP-16, EPOCH and VIDL) 10 15.9
Involved field radiation therapy 15 23.8
Response to primary chemotherapy
CR/PR 34/7 54.0/11.1
SD or PD 18 28.6
Non-measurable 4 6.3
Performance of autologous stem cell
transplantation
9 14.3
Treatment-related toxicity 5 7.9
Abbreviations: No., number; PTCL, peripheral T-cell lymphoma; IPI, international
prognostic index; PIT, prognostic index for PTCL-U; CR, complete remission; PR,
partial response; SD, stable disease; PD, progressive disease.
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followed by IFRT. Fifty-nine patients underwent interim
PET/CT based on the three parameters. Twenty-four
patients (38.1%) were classified as having a positive meta-
bolic uptake (grade 4 and 5) based on the visual assess-
ment using 5-PS. According to the response after primary
chemotherapy, 34 (54.0%) patients achieved a complete
response (CR), 7 (11.1%) achieved a partial response (PR),
and 18 (28.6%) showed stable disease (SD) or progression.
Nine (14.3%) patients, including those with PR afterprimary chemotherapy or with high-risk factors, under-
went autologous stem cell transplantation as a frontline
consolidation. Relapse occurred in 36 patients (57.1%),
and the treatment-related mortality was 7.9%. After a me-
dian follow up of 40.3 months (range, 12.8–83.2 months),
the 3-year OS and PFS rates were 48.3 ± 6.4% and 40.1 ±
6.8%, respectively (Figure 1A). There were no differences
in OS depending on histologic subtype, with the exception
of anaplastic large cell lymphoma (P = 0.595, Figure 1B).
PIT exhibited greater differentiation of survival than IPI
(80.8 months in PIT 0–1, 15.0 in PIT 2, and 8.8 months
in PIT 3–4, P = 0.011, Figure 1D). Multivariate analysis
showed that performance status (≥2), visual (5-PS ≥ 4) and
combined (poor responder by all three assessments) as-
sessment in interim PET/CT scans were independent
prognostic variables in PFS.
Prognostic significance of interim PET/CT based on visual
assessment
Interim PET/CT images were analyzed by a consensus of
two nuclear medicine physicians who were unaware of the
clinical information. The sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) of visual assessment (Grade ≥ 3) for the prediction
of disease progression were 69.4%, 65.2%, 87.8%, and
96.1%, respectively. Seven patients showed false-positive
uptake during primary chemotherapy. Five patients with
nasal-type NK/T cell lymphoma continued to have signifi-
cant metabolic uptakes compared with the mediastinal
blood pools that were confirmed to be inflammatory le-
sions by loco-regional biopsy. In addition, two patients
with hot uptake in the gastric and colonic regions were
confirmed to show inflammatory changes by endoscopic
biopsies. In contrast, three patients classified as grade 3 by
visual assessment exhibited false interim PET/CT negativ-
ity; however, the original lesion was partially regressed.
Patients with interim PET/CT-positive (grade 4–5) on
visual assessment showed a higher relapse rate than pa-
tients with interim PET/CT-negative (grade 1–3) (27.3%
vs. 9.9%, P = 0.02). In addition, patients with the interim
PET/CT-positive showed significantly shorter PFS times
compared to patients with interim PET/CT-negative (5.0
vs. 27.0 months, P = 0.000, Figure 2A). However, among
the 35 patients classified as interim PET/CT negative,
9 patients with grade 3 had a poor clinical outcome
compared with 26 with grades 1–2 (8.8 vs. 64.0 months,
P < 0.001; Figure 2B). A high relapse rate in patients
with grade 3 or false-negative interpretation of interim
PET/CT accounted for the difference in survival.
Prognostic significance of interim PET/CT based on
quantitative-assessments
In ROC analysis, the optimal cutoff values for ΔSUVmax
and ΔMTV2.5 were 67.6% with an AUC of 0.673
Figure 1 Kaplan-Meier survival curves for progression-free survival (PFS) and overall survival (OS) in all patients with PTCL (A), and OS
according to histologic subtype (B), IPI risk (C), and PIT risk (D).
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and 98.7% with an AUC of 0.627 (P < 0.001, 95%
CI; 0.590–0.852), respectively. Each interim PET/CT as-
sessment based on the ΔSUVmax cutoff, and ΔMTV2.5
cutoff was predictive of disease progression with relatively
high positive predictive values (PPV) (92.3% and 92.8%,
respectively) and negative predictive values (NPV) (90.0%
and 92.8% respectively) (Table 2).
The response assessment of interim PET/CT based on
the ΔSUVmax, and ΔMTV2.5 showed significant prog-
nostic potential for PFS. Similarly, based on SUV-based
(optimal cutoff value of 67.6%) and MTV-based assess-
ments (optimal cutoff value of 98.7%), the probability of
3-year PFS in the 33 patients who achieved ΔSUVmax >
the optimal cutoff was 52.6% compared with 24.7% in
the 26 patients who failed to achieve the optimal cutoff(P = 0.001). Moreover, the 3-year PFS rate for 31 patients
who achieved ΔMTV2.5 > the optimal cutoff was 49.9%.
Furthermore, the 3-year PFS rate for the 28 patients with
lower than the optimal cutoff of ΔMTV2.5 was 25.9%
(P < 0.005; Figure 2C and D).
Predictive efficacy of Interim PET/CT based on combined
three parameters
Although an interim PET/CT response based on single-
parameter assessment could increase the predictive
power for clinical outcomes, it was unable to distinguish
the outcomes in the good and poor response groups,
particularly in patients with grade 3 or higher or those
with less than the optimal cutoff of ΔSUVmax or
ΔMTV2.5. To increase the predictive accuracy of in-
terim PET/CT, we divided patients into three groups
Figure 2 Kaplan-Meier survival curves of PFS according to Deauville five-point scale (A, B), the SUVmax reduction rate with the optimal
cutoff value of 67.6% (C), and the MTV2.5 reduction rate with the optimal cutoff value of 98.7% in interim PET/CT (D).
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sponses based on the visual, SUV-based, and MTV-
based assessments. This combined assessment using the
three parameters consisted of each adverse response, in-
cluding grade 4 or 5 in 5-PS and little reduction in the
optimal cutoffs of ΔSUVmax and ΔMTV2.5: i) favorable
responders were satisfied with no adverse response
assessed by the three parameters, ii) poor responders hadTable 2 Receiver operating characteristic (ROC) values for pre
Assessment parameter Sn (%) Sp (%) PPV (%)
Visual assessment (Grade≥ 3) 69.4 65.2 87.8
ΔSUVmax cutoff 81.8 58.3 92.3
ΔMTV2.5 cutoff 77.3 61.1 92.8
Abbreviations: Sn, sensitivity; Sp, specificity; PPV, positive predictive value, NPV, neg
uptake value; ΔMTV2.5, reduction rate of metabolic tumor volume.three adverse responses, and iii) intermediate responders
were satisfied with one or two adverse responses in three
parameters. The clinical outcomes of patients in the favor-
able group were significantly superior to those of patients
in the poor or intermediate responder group (P = 0.002,
P = 0.004, respectively, Figure 3A, B). This classification
based on the “poor” response category of visual, ΔSUVmax
and ΔMTV2.5 assessments on interim PET/CT showed thedicting disease progression
NPV (%) Area under ROC curves 95% CI P value
96.1 0.731 0.597-0.864 0.003
90.0 0.673 0.626-0.874 0.002
93.5 0.627 0.590-0.852 0.005
ative predictive value, ΔSUVmax, reduction rate of the maximal standardized
Figure 3 Kaplan-Meier survival curves of PFS (A) and OS (B) according to groups classified by the three parameters and consisting of
grade 4 or 5 in 5-PS, low reduction of the optimal cutoff of ΔSUVmax and ΔMTV2.5.
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with single-parameter assessment.
Discussion
Currently, evaluation of the interim response using PET/
CT is considered predictive of early relapse and/or re-
duced survival in diffuse large B-cell lymphoma (DLBCL)
and Hodgkin’s lymphoma (HL) [28]. In DLBCL, patients
achieving interim PET negativity after two or four cycles
of chemotherapy generally had more favorable outcomes
compared with those who were interim PET-positive
[29-31]. The prognostic role of interim PET/CT in PTCL
is less-well established than that in DLBCL. One study re-
ported that negative interim or post-therapy interim PET/
CT did not associate with improved the survival In NK-T
cell lymphoma [32]. However, some recent studies have
suggested that the interim PET response may be also use-
ful for predicting the outcome in PTCL. A retrospective
study of mature T-cell and NK/T cell lymphoma reported
that patients achieving interim PET/CT negativity showed
an improved 2-year PFS and OS compared with those
with interim PET/CT positivity [33]. Another retrospect-
ive study yielded similar results regarding the prognostic
role of interim PET/CT [34]. However, the major draw-
back in these reports was the lack of uniformity or reliable
criteria for interim PET interpretation.
Although visual analysis using 5-PS or quantitative im-
aging assessment is generally used to interpret interim
PET/CT, each method has limitations if used alone to
interpret interim PET/CT. Visual comparison of FDGuptake can be optically distorted due to different back-
ground levels and inter-rater discrepancy [35]. For ex-
ample, a previous study reported that about 22% of the
cases may have discrepant Deauville scores between the
two independent readers [36]. Moreover, a study con-
ducted in patients with HL suggested that quantitative
assessment could better predict outcome than visual
analysis [37]. However, the mid-treatment quantitative
assessment also has several limitations, such as the def-
inition of positivity within inter-observer interpretations,
the need to consider the volumetric changes of tumors
during chemotherapy, and the interpretation of minimal
residual uptake at sites of physiologic anatomical FDG
uptake. As the use of quantitative assessment combined
with Deauville scores could be very efficient in discrim-
inating among survival outcomes, we previously ana-
lyzed interim PET/CT using a combination of the visual,
ΔSUVmax, and ΔMTV2.5 parameters and classified sub-
jects into three groups: favorable, intermediate, and poor
responders in DLBCL [38].
In the present study, two nuclear medicine physicians
interpreted the PET/CT scans at the same time to de-
crease the discrepancy rate between observers. In
addition, quantitative assessment with ΔMTV2.5 cutoff
was helpful for predicting the progression during mid-
therapy. Therefore, the response assessment of interim
PET/CT based on the percentage of MTV reduction
should be adapted to assess response early or would be
helpful in increasing the predictive value combined with
SUV-based assessment during the course of primary
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tients suggested that each interim PET/CT response
based on 5-PS, ΔSUVmax, and ΔMTV2.5 after three
and four courses of induction treatment had predictive
value for PFS in patients with PTCL; no significant dif-
ference was observed between the visual and quantita-
tive assessments for predicting the progression.
Furthermore, the threshold value of visual assessment
for distinguishing outcomes is another major concern of
using interim PET/CT as a predictive marker. 4th Inter-
national Workshop on PET held in Menton suggested
that interim PET/CT image were graded as negative or
positive by comparison of initial PET/CT and grade 1–3
considered as negative and grade 4–5 considered for
positive. However, this grading process is independent of
the size of the residual tumor and it may be appropriate
to restrict the complete metabolic response category to
grades 1 and 2 in some situation [39]. In the current
study, patients with grade 3 experienced poor clinical
outcomes compared with patients with grade 1 and 2.
The different clinical outcomes resulted from high re-
lapse rate or false negative uptakes in patients with grade
3. The definition of positivity using grade 1–2 reported
relatively low PPV with high NPV compared to quantita-
tive assessments in ROC analysis. Low PPV could make
it difficult to modify the therapeutic plans with interim
PET-adapted dose escalation or high-dose chemotherapy
in poor responders. Therefore, it was reported that the
combined assessment using the three parameters was
identified to be more predictive of survival outcomes
compared with single-parameter assessment, and this
combined approach may help to overcome the limita-
tions of interim PET/CT evaluation.
Conclusions
Visual, quantitative SUV-based, and MTV-based assess-
ment in interim PET/CT showed prognostic significance
for mid-treatment response analysis in patients with
PTCL, and the combined approach using the three pa-
rameters could have more predictive accuracy for disease
progression between patients with different survival out-
comes compared with single-parameter assessment.
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